Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuerui Huang

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Trends in Genetics : TIG|September 5, 2018
RNA, Action through InteractionsTri C Nguyen, Kathia Zaleta-Rivera, Xuerui Huang, et al.
Iscience|September 22, 2018
RNAs as Proximity-Labeling Media for Identifying Nuclear Speckle Positions Relative to the GenomeWeizhong Chen, Zhangming Yan, Simin Li, et al.
Cytokine: X|February 19, 2021
Value of serum cytokine biomarkers TNF-α, IL-4, sIL-2R and IFN-γ for use in monitoring bacterial load and anti-tuberculosis treatment progressWenjuan Nie, Jun Wang, Wei Jing, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|February 7, 2016
[Treatment effect analysis of the standard regimen and the optimized regimen for retreatment pulmonary tuberculosis complicated with diabetes]Jian Du, Weiwei Gao, Yan Ma, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2019
Genome-wide colocalization of RNA-DNA interactions and fusion RNA pairsZhangming Yan, Norman Huang, Weixin Wu, et al.
BMC Medicine|October 15, 2024
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
Frontiers in Public Health|February 13, 2023
Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in ChinaQiping Ge, Yan Ma, Lijie Zhang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Trends in Genetics : TIG|September 5, 2018
RNA, Action through InteractionsTri C Nguyen, Kathia Zaleta-Rivera, Xuerui Huang, et al.
Iscience|September 22, 2018
RNAs as Proximity-Labeling Media for Identifying Nuclear Speckle Positions Relative to the GenomeWeizhong Chen, Zhangming Yan, Simin Li, et al.
Cytokine: X|February 19, 2021
Value of serum cytokine biomarkers TNF-α, IL-4, sIL-2R and IFN-γ for use in monitoring bacterial load and anti-tuberculosis treatment progressWenjuan Nie, Jun Wang, Wei Jing, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|February 7, 2016
[Treatment effect analysis of the standard regimen and the optimized regimen for retreatment pulmonary tuberculosis complicated with diabetes]Jian Du, Weiwei Gao, Yan Ma, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2019
Genome-wide colocalization of RNA-DNA interactions and fusion RNA pairsZhangming Yan, Norman Huang, Weixin Wu, et al.
BMC Medicine|October 15, 2024
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
Frontiers in Public Health|February 13, 2023
Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in ChinaQiping Ge, Yan Ma, Lijie Zhang, et al.
Pageof 1